RUA Life Sciences plc announced that it has signed an agreement with Corcym SRL ("Corcym"), a global medical device company focussed on the structural heart area, to bring RUA's range of large bore vascular grafts to market. Corcym and RUA have signed a global distribution agreement that grants Corcym the exclusive rights to commercialise RUA's large bore straight and aortic root grafts for heart surgeons. Corcym will leverage its sales team and network already serving the needs of the surgeon, who will use the graft products.

To provide Corcym with the necessary flexibility to maximise market penetration, a novel partnership model has been agreed whereby rather than agree specific price points by territory, the partnership ethos of the agreement will see RUA and Corcym share the gross margin achieved on global sales on a 50:50 basis. Corcym is a global medical device company focused on serving the needs of heart surgeons and their patients. Corcym's current product portfolio includes a wide range of heart valves and heart repair products.

Corcym has a commercial presence servicing heart surgeons in over 100 countries. RUA has a pipeline of vascular grafts in development for the repair of diseased and damaged blood vessels, including the thoracic aorta. The total global market size for the pipeline products is estimated by RUA to be around $1 billion annually.

These products include large bore straight and aortic root grafts together with specialised products for aortic arch repair. The regulatory strategies and plans for the pipeline products have been agreed and RUA anticipates a number of regulatory approvals from 2025 through 2027, allowing Corcym to commercialise the grafts.